Pharmacological profile of mepolizumab
Authors:
Norbert Pauk
Authors‘ workplace:
Klinika pneumologie 3. LF UK a Fakultní nemocnice Bulovka, Praha
Published in:
Vnitř Lék 2023; 69(5): 322-328
Category:
doi:
https://doi.org/10.36290/vnl.2023.063
Overview
An elevated number of eosinophils have been implicated in several type 2 inflammatory chronic diseases that occur at various sites in the body. Over the past 20 years, our knowledge of diseases associated with increased numbers of eosinophils has advanced thanks to the development of drugs that can reduce or even eliminate eosinophils. One such agent is mepolizumab, a humanized monoclonal antibody that binds to interleukin -5 (IL-5). This article briefly and clearly summarizes the pharmacological profile of mepolizumab and its current indications for a number of chronic eosinophilic diseases.
Keywords:
mepolizumab – severe eosinophilic asthma (SEA) – chronic rhinosinusitis with nasal polyps (CRSwNP) – eosinophilic granulomatosis with polyangiitis (EGPA) – hypereosinophilic syndrome (HES).
Sources
- Matera MG, Calzetta L, Rogliani P, Cazzola M. Monoclonal antibodies for severe asthma: Pharmacokinetic profiles. Respir Med. 2019 Jul;153:3-13. doi: 10.1016/j.rmed.2019.05.005. Epub 2019 May 13. PMID: 31136930.
- Hammad H, Lambrecht BN. The basic immunology of asthma. Cell. 2021 Mar 18;184(6):1469-1485. doi: 10.1016/j.cell.2021.02.016. Epub 2021 Mar 11. Erratum in: Cell. 2021 Apr 29;184(9):2521-2522. PMID: 33711259.
- GINA (Global Initiative for Asthma). Global Strategy for Asthma Management and Prevention. 2022. http://www.ginasthma.org
- Teřl M, Sedlák V, Krčmová I. Doporučený postup diagnostiky a léčby těžkého astmatu. Stud. Pneumol. Phthiseol. 82, č. 4, 2022.
- Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012 Aug 18;380(9842):6519. doi: 10.1016/S0140-6736(12)60988-X. PMID: 22901886.
- Ortega HG, Liu MC, Pavord ID, et al; Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014 Sep 25;371(13):1198-207. doi: 10.1056/NEJMoa1403290. Epub 2014 Sep 8. Erratum in: N Engl J Med. 2015 Apr 30;372(18):1777. PMID: 25199059.
- Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014 Sep 25;371(13):1189-97. doi: 10.1056/ NEJMoa1403291. Epub 2014 Sep 8. PMID: 25199060.
- Gibson PG, Prazma CM, Chupp GL, et al. Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions. Respir Res. 2021 Jun 7;22(1):171. doi: 10.1186/s12931-021-01746-4. PMID: 34098955; PMCID: PMC8182929.
- Khurana S, Brusselle GG, Bel EH, et al. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study. Clin Ther. 2019 Oct;41(10):2041-2056.e5. doi: 10.1016/j.clinthera.2019.07.007. Epub 2019 Aug 22. PMID: 31447130.
- Harrison T, Canonica GW, Chupp G, et al. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. Eur Respir J. 2020 Oct 15;56(4):2000151. doi: 10.1183/13993003.00151-2020. PMID: 32817259; PMCID: PMC7559868.
- Pilette C, Canonica GW, Chaudhuri R, et al. REALITI-A Study: Real-World Oral Corticosteroid-Sparing Effect of Mepolizumab in Severe Asthma. J Allergy Clin Immunol Pract. 2022 Oct;10(10):2646-2656. doi: 10.1016/j.jaip.2022.05.042. Epub 2022 Jun 24. PMID: 35753668. 12.
- Hellings PW, Verhoeven E, Fokkens WJ. State-of-the-art overview on biological treatment for CRSwNP. Rhinology. 2021 Apr 1;59(2):151-163. doi: 10.4193/Rhin20.570. PMID: 33459728.
- Han JK, Bachert C, Fokkens W, Desrosiers M, et al. SYNAPSE study investigators. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021 Oct;9(10):1141-1153. doi: 10.1016/S2213-2600(21)00097-7. Epub 2021 Apr 16. PMID: 33872587.
- Raffray L, Guillevin L. Updates for the treatment of EGPA. Presse Med. 2020 Oct;49(3):104036. doi: 10.1016/j.lpm.2020.104036. Epub 2020 Jul 8. PMID: 32652104.
- Moiseev S, Cohen Tervaert JW, Arimura Y, et al. 2020 international consensus on ANCA testing beyond systemic vasculitis. Autoimmun Rev. 2020 Sep;19(9):102618. doi: 10.1016/j.autrev.2020.102618. Epub 2020 Jul 12. PMID: 32663621.
- Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med. 2017 May 18;376(20):1921-1932. doi: 10.1056/ NEJMoa1702079. PMID: 28514601; PMCID: PMC5548295.
- Žurkova M, Jakubec P, Lošťáková V, et al.Mepolizumab v léčbě eozinofilní granulomatózy s polyangiitidou. Remedia. 2023;33:1-6.
- Requena G, van den Bosch J, Akuthota P, et al. Clinical Profile and Treatment in Hypereosinophilic Syndrome Variants: A Pragmatic Review. J Allergy Clin Immunol Pract. 2022 Aug;10(8):2125-2134. doi: 10.1016/j.jaip.2022.03.034. Epub 2022 Apr 22. PMID: 35470096.
- Roufosse F, Kahn JE, Rothenberg ME, et al. HES Mepolizumab study group. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020 Dec;146(6):1397-1405. doi: 10.1016/j. jaci.2020.08.037. Epub 2020 Sep 18. PMID: 32956756; PMCID: PMC9579892.
- Domingo Ribas C, Carrillo Díaz T, Blanco Aparicio M, et al. REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study. Drugs. 2021 Oct;81(15):1763-1774. doi: 10.1007/ s40265-021-01597-9. Epub 2021 Sep 29. Erratum in: Drugs. 2021 Oct 21;: PMID: 34586602; PMCID: PMC8550660.
- Nucala 100 mg inj plv sol 1, Available from: www.sukl.cz.
- Národní centra těžkého astmatu; Available from: www.tezke-astma.cz.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2023 Issue 5
Most read in this issue
- Acute kidney injury in patients with cirrhosis – practical summary
- Dyslipidemia – the known unknown
- Cardiovascular disease and kidney transplantation
- News in respiratory medicine